Nexrutine® preserves muscle mass similar to exercise in prostate cancer mouse model
Abstract Muscle loss is a debilitating side effect to prostate cancer (PCa) experienced by nearly 60% of men. The purpose of this study was to test the hypothesis that Nexrutine®, a bark extract from the Phellodendrum amurense, can protect against prostate cancer induced muscle loss in a similar man...
Main Authors: | Darpan I. Patel, Derek Wallace, Kira Abuchowski, Paul Rivas, Amber Gallegos, Nicolas Musi, Addanki Pratap. Kumar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-08-01
|
Series: | Physiological Reports |
Subjects: | |
Online Access: | https://doi.org/10.14814/phy2.14217 |
Similar Items
-
The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer
by: Patrick J. Owen, et al.
Published: (2019-10-01) -
Metformin Attenuates Slow-to-Fast Fiber Shift and Proteolysis Markers Increase in Rat Soleus after 7 Days of Rat Hindlimb Unloading
by: Kristina A. Sharlo, et al.
Published: (2022-12-01) -
Trends in prostate cancer research /
by: Lucas, John N.
Published: (2005) -
Anterior prostate biopsy at initial and repeat evaluation: is it useful to detect significant prostate cancer?
by: Pietro Pepe, et al.
Published: (2015-10-01) -
Prostatic Inflammation in Prostate Cancer: Protective Effect or Risk Factor?
by: Alessandro Tafuri, et al.
Published: (2021-06-01)